William P. Clarke

William P. Clarke

Auto-generated profile, based on publicly available information

William P. Clarke

Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
JUJonathan D. Urban
Jonathan D. Urban
WCWilliam P. Clarke
William P. Clarke
MZMark von Zastrow
Mark von Zastrow
DNDavid E. Nichols
David E. Nichols
BKBrian Kobilka
Brian Kobilka
RMRichard B Mailman
Richard B Mailman
The concept of intrinsic efficacy has been enshrined in pharmacology for half of a century, yet recent data have revealed that many ligands can differentially activate signaling pathways mediated via a single G protein-coupled receptor in a manner that challenges the traditional definition of intrinsic efficacy. Some terms for this phenomenon include functional selectivity, agonist-directed trafficking, and biased agonism. At the extreme, functionally selective ligands may be both agonists and antagonists at different functions mediated by the same receptor. Data illustrating this phenomenon are presented from serotonin, opioid, dopamine, vasopressin, and adrenergic receptor systems. A variety of mechanisms may influence this apparently ubiquitous phenomenon. It may be initiated by differences in ligand-induced intermediate conformational states, as shown for the β2-adrenergic receptor. Subsequent mechanisms that may play a role include diversity of G proteins, scaffolding and signaling partners, and receptor oligomers. Clearly, expanded research is needed to elucidate the proximal (e.g., how functionally selective ligands cause conformational changes that initiate differential signaling), intermediate (mechanisms that translate conformation changes into differential signaling), and distal mechanisms (differential effects on target tissue or organism). Besides the heuristically interesting nature of functional selectivity, there is a clear impact on drug discovery, because this mechanism raises the possibility of selecting or designing novel ligands that differentially activate only a subset of functions of a single receptor, thereby optimizing therapeutic action. It also may be timely to revise classic concepts in quantitative pharmacology and relevant pharmacological conventions to incorporate these new concepts.

1 July 1998 in Molecular Pharmacology
Verified
Journal Article
Closed access
KBKelly A. Berg
Kelly A. Berg
SMSaul Maayani
Saul Maayani
JGJoseph Goldfarb
Joseph Goldfarb
CSClare Scaramellini
Clare Scaramellini
PLPaul Leff
Paul Leff
WCWilliam P. Clarke
William P. Clarke
There are many examples of a single receptor coupling directly to more than one cellular signal transduction pathway. Although traditional receptor theory allows for activation of multiple cellular effectors by agonists, it predicts that the relative degree of activation of each effector pathway by an agonist (relative efficacy) must be the same. In the current experiments, we demonstrate that agonists at the human serotonin2A (5-HT2A) and 5-HT2Creceptors activate differentially two signal transduction pathways independently coupled to the receptors [phospholipase C (PLC)-mediated inositol phosphate (IP) accumulation and phospholipase A2(PLA2)-mediated arachidonic acid (AA) release]. The relative efficacies of agonists differed depending on which signal transduction pathway was measured. Moreover, relative to 5-HT, some 5-HT2C agonists (e.g., 3-trifluoromethylphenyl-piperazine) preferentially activated the PLC-IP pathway, whereas others (e.g., lysergic acid diethylamide) favored the PLA2-AA pathway. In contrast, when two dependent responses were measured (IP accumulation and calcium mobilization), agonist relative efficacies were not different. These data strongly support the hypothesis termed “agonist-directed trafficking of receptor stimulus” recently proposed by Kenakin [Trends Pharmacol Sci16:232–238 (1995)]. Concentration-response curves to 5-HT2C agonists were fit well by a three-state model of receptor activation, suggesting that two active receptor states may be sufficient to explain pathway-dependent agonist efficacy. Rational drug design that optimizes preferential effector activity within a group of receptor-selective drugs holds the promise of increased selectivity in clinically useful agents.

31 March 2004 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
Philippe De DeurwaerderePhilippe De Deurwaerdere
Philippe De Deurwaerdere
SNSylvia Navailles
Sylvia Navailles
KBKelly A Berg
Kelly A Berg
WCWilliam P. Clarke
William P. Clarke
USUmberto Spampinato
Umberto Spampinato
Numerous research has pointed out that serotonin2c (5-HT2C) receptor, a subtype of 5-HT receptors belonging to the G-protein-coupled receptor superfamily, modulates the activity of mesencephalic dopamine (DA) neurons, the dysfunction of which is involved in devastating diseases such as schizophrenia, Parkinson's disease, and drug addiction. In the present study, usingin vivointracerebral microdialysis and Chinese hamster ovary (CHO) cells expressing 5-HT2Creceptors to identify appropriate 5-HT2Creceptor ligands, we sought to determine whether the property of 5-HT2Creceptors to spontaneously activate intracellular signaling pathwaysin vitro(constitutive activity) participates in the tonic inhibitory control that they exert on DA release in the rat striatum and nucleus accumbensin vivo. In CHO cells, the purported antagonist 5-methyl-1-(3-pyridylcarbamoyl)-1,2,3,5-tetrahydropyrrolo[2,3-f] indole hydrochloride (SB 206553), but not 6-chloro-5-methyl-1-[6-(2-methylpiridin-3-yloxy)pyridin-3-yl carbamoyl] indoline (SB 242084), decreased basal inositol phosphate accumulation, thus behaving as a 5-HT2Cinverse agonist. Its effect was prevented by SB 242084.In vivo, SB 206553 (1–10 mg/kg) elicited a dose-dependent and clear-cut increase in accumbal and striatal DA release compared with SB 242084 (1–10 mg/kg), and the 5-HT2CagonistS-2-(6-chloro-5-fluoroindol-1-yl)-1-methylethylamine hydrochloride (Ro-60-0175) (0.3–3 mg/kg) inhibited DA release. Pretreatment by SB 242084 reversed the change in DA release elicited by Ro-60-0175 and SB 206553. Furthermore, SB 206553-stimulated DA release was insensitive to reduction of 5-HT neuronal function induced by the 5-HT1Aagonist (±)-8-hydroxy-2-dipropylaminotetralin or intra-raphe injections of 5,7-dihydroxytryptamine neurotoxin. The obtained results provide the firstin vivoevidence that constitutive activity of the 5-HT2Creceptor tonically inhibits mesencephalic DA neurons and underscore the need for a better understanding of the pathophysiological role of constitutive receptor activity.

6 August 2018 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
KBKelly A Berg
Kelly A Berg
WCWilliam P Clarke
William P Clarke
Constitutive receptor activity/inverse agonism and functional selectivity/biased agonism are 2 concepts in contemporary pharmacology that have major implications for the use of drugs in medicine and research as well as for the processes of new drug development. Traditional receptor theory postulated that receptors in a population are quiescent unless activated by a ligand. Within this framework ligands could act as agonists with various degrees of intrinsic efficacy, or as antagonists with zero intrinsic efficacy. We now know that receptors can be active without an activating ligand and thus display “constitutive” activity. As a result, a new class of ligand was discovered that can reduce the constitutive activity of a receptor. These ligands produce the opposite effect of an agonist and are called inverse agonists. The second topic discussed is functional selectivity, also commonly referred to as biased agonism. Traditional receptor theory also posited that intrinsic efficacy is a single drug property independent of the system in which the drug acts. However, we now know that a drug, acting at a single receptor subtype, can have multiple intrinsic efficacies that differ depending on which of the multiple responses coupled to a receptor is measured. Thus, a drug can be simultaneously an agonist, an antagonist, and an inverse agonist acting at the same receptor. This means that drugs have an additional level of selectivity (signaling selectivity or “functional selectivity”) beyond the traditional receptor selectivity. Both inverse agonism and functional selectivity need to be considered when drugs are used as medicines or as research tools.

28 September 2005 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
APAmol M. Patwardhan
Amol M. Patwardhan
KBKelly A. Berg
Kelly A. Berg
AAArmen N. Akopain
Armen N. Akopain
NJNathaniel A. Jeske
Nathaniel A. Jeske
NGNikita Gamper
Nikita Gamper
KHKenneth M. Hargreaves
Kenneth M. Hargreaves
Peripheral opioid analgesia is increased substantially after inflammation. We evaluated the hypothesis that an inflammatory mediator, bradykinin (BK), evokes functional competence of the δ-opioid receptor (DOR) for inhibiting trigeminal ganglia (TG) sensory neurons. We also evaluated whether BK evokes trafficking of the DOR to the plasma membrane. Rat TG cultures were pretreated with BK (10 μm) or vehicle, and the effects of DOR agonists ([d-Pen2,5]-enkephalin or [d-Ala2,d-Leu5]-enkephalin) on BK (10μm)/prostagladin E2 (PGE2; 1 μm)-stimulated immunoreactive calcitonin gene-related peptide (iCGRP) release or PGE2 (1 μm)-stimulated cAMP accumulation were measured. The effect of BK treatment on opioid receptor trafficking was evaluated by DOR immunohistochemistry, cell-surface DOR biotinylation, and live imaging of neurons transfected with mDOR–green fluorescent protein. BK pretreatment rapidly and significantly increased DOR agonist inhibition of evoked iCGRP release and cAMP accumulation. These effects of BK pretreatment were blocked by a B2receptor antagonist (HOE-140; 10μm) or a protein kinase C (PKC) inhibitor [bisindolymaleimide (BIS); 1μm]. Moreover, BK treatment rapidly and significantly increased the accumulation of DOR in the plasma membrane. However, BK-induced trafficking of DOR was not reversed by pretreatment with BIS, nor was trafficking evoked by application of a PKC activator PMA (200 nm). These data suggest that BK, in a PKC-dependent manner, induces rapid functional competence of DOR for inhibiting TG nociceptors and in a PKC-independent manner rapidly induces trafficking of DOR to the plasma membrane. These findings indicate that exposure to certain inflammatory mediators rapidly alters the signaling properties and neuronal localization of DOR, possibly contributing to peripheral opioid analgesia.

1 September 2001 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
KBKelly Berg
Kelly Berg
JCJodie D Cropper
Jodie D Cropper
CNColleen M Niswender
Colleen M Niswender
ESElaine Sanders‐Bush
Elaine Sanders‐Bush
RERonald B Emeson
Ronald B Emeson
WCWilliam P Clarke
William P Clarke
The serotonin2C (5‐HT2C) receptor couples to both phospholipase C (PLC)‐inositol phosphate (IP) and phospholipase A2 (PLA2)‐arachidonic acid (AA) signalling cascades. Agonists can differentially activate these effectors (i.e. agonist‐directed trafficking of receptor stimulus) perhaps due to agonist‐specific receptor conformations which differentially couple to/activate transducer molecules (e.g. G proteins). Since editing of RNA transcripts of the human 5‐HT2C receptor leads to substitution of amino acids at positions 156, 158 and 160 of the putative second intracellular loop, a region important for G protein coupling, we examined the capacity of agonists to activate both the PLC‐IP and PLA2‐AA pathways in CHO cells stably expressing two major, fully RNA‐edited isoforms (5‐HT2C‐VSV, 5‐HT2C‐VGV) of the h5‐HT2C receptor. 5‐HT increased AA release and IP accumulation in both 5‐HT2C‐VSV and 5‐HT2C‐VGV expressing cells. As expected, the potency of 5‐HT for both RNA‐edited isoforms for both responses was 10 fold lower relative to that of the non‐edited receptor (5‐HT2C‐INI) when receptors were expressed at similar levels. Consistent with our previous report, the efficacy order of two 5‐HT receptor agonists (TFMPP and bufotenin) was reversed for AA release and IP accumulation at the non‐edited receptor thus demonstrating agonist trafficking of receptor stimulus. However, with the RNA‐edited receptor isoforms there was no difference in the relative efficacies of TFMPP or bufotenin for AA release and IP accumulation suggesting that the capacity for 5‐HT2C agonists to traffic receptor stimulus is lost as a result of RNA editing. These results suggest an important role for the second intracellular loop in transmitting agonist‐specific information to signalling molecules. British Journal of Pharmacology (2001) 134, 386–392; doi:10.1038/sj.bjp.0704255